Growth Hormone Improves Social Impairments From Autism Linked Disorder
New research has found that a growth hormone can significantly improve the social impairment associated with autism spectrum disorder (ASD) in patients with a related genetic syndrome. The pilot study, conducted at the Icahn School of Medicine at Mount Sinai, focused on the use of insulin-like growth factor-1 (IGF-1) to treat Phelan-McDermid syndrome (PMS), a disorder caused by a deletion or mutation of the SHANK3 gene on chromosome 22. “Ours is the first controlled trial of any treatment for Phelan-McDermid syndrome,” said Alexander Kolevzon, MD, clinical director of the Seaver Autism Center at the Icahn School of Medicine at Mount Sinai.
- Dr. Alexander Kolevzon, Associate Professor, Psychiatry, Pediatrics, Clinical Director, the Seaver Autism Center at the Icahn School of Medicine at Mount Sinai
Additional Coverage:
Business Standard
News-Medical
Medical Xpress
Zee News
Researchers Develop AI Model That Maps How Genes Work Together in Human Cells
May 21, 2026 View All Press Releases
Mount Sinai Launches the Marilyn Monroe Mental Health for the Arts Program
Apr 30, 2026 View All Press Releases
Mount Sinai’s Emma Guttman, MD, PhD, Elected to the Association of American Physicians
Apr 22, 2026 View All Press Releases
